Chris Andersen has spent a career treating subarachnoid haemorrhage, and he opens this episode by admitting we might have wasted a fortune treating vasospasm without evidence to show for it. Host Oli Flower and Chris Andersen, co-conveners of ISAH 2026, dig into why SAH care hasn't seen the revolution ischaemic stroke has, why delayed cerebral ischaemia (DCI) is the field's great unsolved problem, and why fewer than 10% of SAH trials have ever asked patients what actually matters to them. Chris Andersen is a neurocritical care specialist and co-convener of ISAH 2026, the International Conference on Subarachnoid Haemorrhage, running 17–20 November in Sydney. In this episode: <ul class= "[li_&]:mb-0 [li_&]:mt-1 [li_&]:gap-1 [&:not(:last-child)_ul]:pb-1 [&:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3 print:block print:space-y-1" dir="ltr"> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 02:56 — If you could solve one problem in SAH in the next decade, what would it be?</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 03:52 — Have outcomes actually improved in the last 15 years?</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 05:52 — The treatment we've poured money into without proof it works</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 08:53 — Is DCI the ARDS of subarachnoid haemorrhage?</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 10:30 — Precision medicine: substance or buzzword?</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 13:32 — What AI can realistically do for SAH care in the next 5 years</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 16:56 — The best debates coming to ISAH 2026</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 19:12 — Lumbar drains and the EARLYDRAIN trial, three years on</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 22:23 — Platform trials: the future, or an expensive way to spend grant money?</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 26:23 — What clinicians get wrong about recovery — and what patients actually want measured</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 32:11 — The tech that sounds like science fiction but might be routine in 10 years</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 35:40 — Why SAH needs a global alliance, not another society</li> <li class= "font-claude-response-body whitespace-normal break-words pl-2"> 39:26 — Lightning round: most overrated treatment, biggest unanswered question, and a prediction Chris might regret</li> </ul> ISAH 2026 runs 17–20 November in Sydney. View the program and register at <a href= "https://www.subarachnoid.org/register">subarachnoid.org</a>

Chris Andersen has spent a career treating subarachnoid haemorrhage, and he opens this episode by admitting we might have wasted a fortune treating vasospasm without evidence to show for it. Host Oli Flower and Chris Andersen, co-conveners of ISAH 2026, dig into why SAH care hasn't seen the revolution ischaemic stroke has, why delayed cerebral ischaemia (DCI) is the field's great unsolved problem, and why fewer than 10% of SAH trials have ever asked patients what actually matters to them. Chris Andersen is a neurocritical care specialist and co-convener of ISAH 2026, the International Conference on Subarachnoid Haemorrhage, running 17–20 November in Sydney. In this episode: 02:56 — If you could solve one problem in SAH in the next decade, what would it be? 03:52 — Have outcomes actually improved in the last 15 years? 05:52 — The treatment we've poured money into without proof it works 08:53 — Is DCI the ARDS of subarachnoid haemorrhage? 10:30 — Precision medicine: substance or buzzword? 13:32 — What AI can realistically do for SAH care in the next 5 years 16:56 — The best debates coming to ISAH 2026 19:12 — Lumbar drains and the EARLYDRAIN trial, three years on 22:23 — Platform trials: the future, or an expensive way to spend grant money? 26:23 — What clinicians get wrong about recovery — and what patients actually want measured 32:11 — The tech that sounds like science fiction but might be routine in 10 years 35:40 — Why SAH needs a global alliance, not another society 39:26 — Lightning round: most overrated treatment, biggest unanswered question, and a prediction Chris might regret ISAH 2026 runs 17–20 November in Sydney. View the program and register at subarachnoid.org

Chris Andersen has spent a career treating subarachnoid haemorrhage, and he opens this episode by admitting we might have wasted a fortune treating vasospasm without evidence to show for it. Host Oli Flower and Chris Andersen, co-conveners of ISAH 2026, dig into why SAH care hasn't seen the revolution ischaemic stroke has, why delayed cerebral ischaemia (DCI) is the field's great unsolved problem, and why fewer than 10% of SAH trials have ever asked patients what actually matters to them. Chris Andersen is a neurocritical care specialist and co-convener of ISAH 2026, the International Conference on Subarachnoid Haemorrhage, running 17–20 November in Sydney. In this episode: <ul> <li> 02:56 — If you could solve one problem in SAH in the next decade, what would it be?</li> <li> 03:52 — Have outcomes actually improved in the last 15 years?</li> <li> 05:52 — The treatment we've poured money into without proof it works</li> <li> 08:53 — Is DCI the ARDS of subarachnoid haemorrhage?</li> <li> 10:30 — Precision medicine: substance or buzzword?</li> <li> 13:32 — What AI can realistically do for SAH care in the next 5 years</li> <li> 16:56 — The best debates coming to ISAH 2026</li> <li> 19:12 — Lumbar drains and the EARLYDRAIN trial, three years on</li> <li> 22:23 — Platform trials: the future, or an expensive way to spend grant money?</li> <li> 26:23 — What clinicians get wrong about recovery — and what patients actually want measured</li> <li> 32:11 — The tech that sounds like science fiction but might be routine in 10 years</li> <li> 35:40 — Why SAH needs a global alliance, not another society</li> <li> 39:26 — Lightning round: most overrated treatment, biggest unanswered question, and a prediction Chris might regret</li> </ul> ISAH 2026 runs 17–20 November in Sydney. View the program and register at <a href="https://www.subarachnoid.org/register" rel="noopener noreferrer">subarachnoid.org</a>

Andersen — Have We Actually Improved SAH Outcomes in 15 Years?

Catherine Bell takes us through how to troubleshoot problems commonly encountered when looking after patients who have an external ventricular drain (EVD) in situ. Issues with using brain tissue oxygen monitors are also discussed. A highly practical session aimed at bedside clinicians. This presentation was delivered by Catherine Bell at <a href="https://codachange.org/" target="_blank" rel= "noopener">CODA2022</a>. Want more content about EVD? Visit <a href="https://bit.ly/neuroresus" target="_blank" rel= "noopener">neuroresus.com</a> or <a href= "http://eepurl.com/iuNLLk">subscribe</a> to be notified of new podcast releases via email. To express your interest in attending the 2024 Neuroresus live course, <a href= "https://docs.google.com/forms/d/1tRRLf55kAv8g1PC1_8bO016M3ecEEbz1KLroIuYEojE/edit?ts=64b63fda">click here</a>.

Catherine Bell takes us through how to troubleshoot problems commonly encountered when looking after patients who have an external ventricular drain (EVD) in situ. Issues with using brain tissue oxygen monitors are also discussed. A highly practical session aimed at bedside clinicians. This presentation was delivered by Catherine Bell at CODA2022. Want more content about EVD? Visit neuroresus.com or subscribe to be notified of new podcast releases via email. To express your interest in attending the 2024 Neuroresus live course, click here.

Catherine Bell takes us through how to troubleshoot problems commonly encountered when looking after patients who have an external ventricular drain (EVD) in situ. Issues with using brain tissue oxygen monitors are also discussed. A highly practical session aimed at bedside clinicians. This presentation was delivered by Catherine Bell at <a href="https://codachange.org/" rel="noopener noreferrer">CODA2022</a>. Want more content about EVD? Visit <a href="https://bit.ly/neuroresus" rel="noopener noreferrer">neuroresus.com</a> or <a href="http://eepurl.com/iuNLLk" rel="noopener noreferrer">subscribe</a> to be notified of new podcast releases via email. To express your interest in attending the 2024 Neuroresus live course, <a href="https://docs.google.com/forms/d/1tRRLf55kAv8g1PC1_8bO016M3ecEEbz1KLroIuYEojE/edit?ts=64b63fda" rel="noopener noreferrer">click here</a>.

EVD tips and tricks

Dr Lucian Roseverne: Interventional radiology: standing member or invite only? From CICM ASM PROGRAM 2019.

Dr Lucian Roseverne: Interventional radiology: standing member or invite only? From CICM ASM PROGRAM 2019.

Interventional radiology: standing member or invite only?

Professor Roy Kimble: Prevention is better than cure. From CICM ASM PROGRAM 2019.

Professor Roy Kimble: Prevention is better than cure. From CICM ASM PROGRAM 2019.

Prevention is better than cure

Dr Nicola Curry: Reversing DOACS. From CICM ASM PROGRAM 2019.

Dr Nicola Curry: Reversing DOACS. From CICM ASM PROGRAM 2019.

Reversing DOACS

Associate Professor Samuel Galvagno: Thromboembolism. From CICM ASM PROGRAM 2019.

Associate Professor Samuel Galvagno: Thromboembolism. From CICM ASM PROGRAM 2019.

Thromboembolism

Professor Stephen Bernard: Tranexamic Acid. From CICM ASM PROGRAM 2019.

Professor Stephen Bernard: Tranexamic Acid. From CICM ASM PROGRAM 2019.

Tranexamic Acid

Associate Professor Craig French: Erythropoietin & other inflammatory modulators. From CICM ASM PROGRAM 2019. Supported by <a href= "https://donatelife.gov.au">Donate Life</a>

Associate Professor Craig French: Erythropoietin & other inflammatory modulators. From CICM ASM PROGRAM 2019. Supported by Donate Life

Associate Professor Craig French: Erythropoietin &amp; other inflammatory modulators. From CICM ASM PROGRAM 2019. Supported by <a href="https://donatelife.gov.au" rel="noopener noreferrer">Donate Life</a>

Erythropoietin & other inflammatory modulators

Professor Chad Ball: Trauma by Remote. From CICM ASM PROGRAM 2019

Professor Chad Ball: Trauma by Remote. From CICM ASM PROGRAM 2019

Trauma by Remote

Dr John O'Neill: Remote Trauma. From CICM ASM PROGRAM 2019

Dr John O'Neill: Remote Trauma. From CICM ASM PROGRAM 2019

Remote Trauma

Associate Professor Dianne Stephens: Why do we need a NCCTRC? From CICM ASM PROGRAM 2019

Associate Professor Dianne Stephens: Why do we need a NCCTRC? From CICM ASM PROGRAM 2019

Why do we need a NCCTRC?

Dr. Stephen Rashford: Anything a Hospital Can Do; I Can Do First. From CICM ASM PROGRAM 2019

Dr. Stephen Rashford: Anything a Hospital Can Do; I Can Do First. From CICM ASM PROGRAM 2019

Share Neuro Resus

Sign up to save your podcasts

Neuro Resus

Neuro Resus episodes

About Neuro Resus

More shows like Neuro Resus

If Books Could Kill

Big Small Talk